Hikma EBIT Jumps 8% on Injectables Stabilisation, R&D Spend to Accelerate

Hikma’s ‘three engines’ strategy—injectables, branded MENA, and Rx—resonates with the biotech ecosystem’s focus on high-barrier-to-entry manufacturing and specialty injectables. The reacceleration of R&D spending signals potential pipeline expansion, while the MENA stockpiling dynamic serves as a reminder of how geopolitical risk creates lumpy but lucrative pharmaceutical demand.

Three London-listed companies—Derwent London, Serco Group, and Hikma Pharmaceuticals—reported first-half 2026 earnings on August 9, each painting a picture of resilient UK corporate performance amid an uncertain macroeconomic backdrop. The thematic threads running through the reports include: stronger-than-expected operating metrics prompting upgraded or reiterated guidance; geopolitical tailwinds and headwinds from defense spending and regional instability; and the emerging role of artificial intelligence in reshaping demand across sectors from offices to pharmaceuticals.

“

Hikma Pharmaceuticals reiterated full-year guidance after reporting near-8% EBIT growth and 5% EPS growth.

Derwent London, the central London office REIT, delivered a standout performance as the West End's chronic supply shortage collided with surging demand—particularly from AI companies. Executive Director Emily Prideaux noted that AI-related office take-up hit 700,000 square feet in the first half, nearly double the entire 2025 total, with a further 600,000 square feet of unsatisfied demand. This contributed to Derwent's highest first-half estimated rental value growth in a decade at 2.6%, accelerating from prior periods, and management upgraded its full-year earnings outlook. The EPRA vacancy rate fell to just 4.4%, and new leases were signed 5.1% above estimated values. Meanwhile, Grade A West End vacancy was a razor-thin 1.2%, underscoring the supply crunch that proptech innovators and flexible workspace operators must navigate. Yet tenant incentives stubbornly remain around 24 months on a 10-year lease, reflecting construction-cost inflation and cautious occupier sentiment despite the headline demand. This tension between bidding pressure and incentive structures is a key dynamic to monitor.

Serco Group, the government services outsourcer, reported constant-currency revenue growth of 4% and underlying operating profit of £157 million. Defense activity was a primary growth driver—hardly surprising given elevated government defense budgets across the UK, Europe, and North America. CEO Anthony Kirby credited productivity initiatives and cost control for margin expansion. The company maintained full-year guidance and expanded its share buyback program, signaling confidence in sustained public-sector outsourcing demand. Serco’s results underscore the booming defense-technical services market, which increasingly integrates digital and cybersecurity capabilities—creating crosswind with the proptech and AI ecosystems as modern defense infrastructure demands smart bases and secure data centers.